Horizon Investments LLC Invests $652,000 in Protagonist Therapeutics, Inc. $PTGX

Horizon Investments LLC purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 7,461 shares of the company’s stock, valued at approximately $652,000.

Several other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its holdings in Protagonist Therapeutics by 11.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after purchasing an additional 146 shares during the period. Farther Finance Advisors LLC grew its stake in Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the last quarter. Parkman Healthcare Partners LLC grew its stake in Protagonist Therapeutics by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock valued at $4,109,000 after purchasing an additional 253 shares during the last quarter. Guggenheim Capital LLC lifted its holdings in shares of Protagonist Therapeutics by 1.6% in the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after buying an additional 303 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after buying an additional 314 shares during the period. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $99.36 on Friday. Protagonist Therapeutics, Inc. has a 1-year low of $42.85 and a 1-year high of $107.84. The stock has a market cap of $6.39 billion, a PE ratio of -54.90 and a beta of 1.89. The stock’s fifty day moving average is $99.40 and its two-hundred day moving average is $89.42.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. The company had revenue of $56.37 million for the quarter, compared to analysts’ expectations of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. On average, research analysts expect that Protagonist Therapeutics, Inc. will post 2.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Citigroup reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a report on Wednesday. Citizens Jmp upped their price target on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research report on Wednesday. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. Jefferies Financial Group restated a “buy” rating and set a $121.00 price target on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Finally, Barclays upped their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $113.69.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Harold E. Selick sold 24,000 shares of the firm’s stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the transaction, the director owned 60,845 shares of the company’s stock, valued at approximately $6,388,725. This trade represents a 28.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 54,641 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $101.00, for a total value of $5,518,741.00. Following the transaction, the chief executive officer directly owned 524,938 shares in the company, valued at approximately $53,018,738. This represents a 9.43% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 138,215 shares of company stock valued at $13,866,186. Corporate insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.